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INTRODUCTION 
 
The abnormal proteinase K (PK)-resistant prion protein 
(PrP
Sc) is the only known component of the infectious 
prions  that  are  associated  with  a  group  of  fatal 
neurodegenerative  disorders  called  prion  diseases  or 
transmissible spongiform encephalopathies [1].  While 
it has been well documented that PrP
Sc is derived from a 
PK-sensitive cellular PrP
C in the central nervous system 
through  an  alpha-helix  to  beta-sheet  structural 
transition, the specific molecular mechanism(s) behind 
the  PrP  conversion  remain  poorly  understood  [2]. 
Several plausible theories have emerged, including the 
prevailing  seeding  model  [3],  which  explains  this 
conversion  with  the  use  of  PrP
Sc  seeds  that  are 
introduced  either  by  exogenous  infection  in  diseases 
such  as  kuru,  iatrogenic  Creutzfeldt-Jakob  disease 
(CJD) and variant CJD, or formed by endogenous PrP
Sc 
molecules including sporadic CJD and various familial 
prion diseases. However, the exact molecular nature of 
the endogenous PrP
Sc has not been elucidated.  
 
In  2006,  we  first  identified  small  amounts  of  PK-
resistant PrP aggregates in uninfected brains of humans, 
cattle and hamsters [4]. Since then, subsequent studies 
have  revealed  similar  insoluble  structures  in  a  wide 
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Abstract: A distinct conformational transition from the α-helix-rich cellular prion protein (PrP
C) into its β-sheet-rich 
pathological isoform (PrP
Sc) is the hallmark of prion diseases, a group of fatal transmissible encephalopathies that 
includes spontaneous and acquired forms. Recently, a PrP
Sc-like intermediate form characterized by the formation of 
insoluble aggregates and protease-resistant PrP species termed insoluble PrP
C (iPrP
C) has been identified in uninfected 
mammalian  brains  and  cultured  neuronal  cells,  providing  new  insights  into  the  molecular  mechanism(s)  of  these 
diseases. Here, we explore the molecular characteristics of the spontaneously formed iPrP
C in cultured neuroblastoma 
cells expressing wild-type or mutant human PrP linked to two familial prion diseases. We observed that although PrP 
mutation  at  either  residue  183  from  Thr  to  Ala  (PrP
T183A)  or  at  residue  198  from  Phe  to  Ser  (PrP
F198S)  affects 
glycosylation at both N-linked glycosylation sites, the T183A mutation that results in intracellular retention significantly 
increased the formation of iPrP
C. Moreover, while autophagy is increased in F198S cells, it was significantly decreased 
in T183A cells. Our results indicate that iPrP
C may be formed more readily in an intracellular compartment and that a 
significant increase in PrP
T183A aggregation may be attributable to the inhibition of autophagy. 
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range of organisms, from cattle and sheep to humans [5] 
and cultured neuroblastoma cells expressing wild-type 
or  mutant  human  PrP  [6].  All  these  studies  provide 
experimental evidence that prion-like forms are present 
at a low level in the normal brain. Such isoforms could 
be either the silent prions or prion precursors proposed 
previously  [3,7]  or  the  recognized  PrP  species 
implicated in long-term memory in healthy humans [8]. 
Neuroblastoma  cell  expressing  various  human  PrP 
mutants  are  an  essential  tool  in  the  study  of  mutant 
prions  linked  to  naturally  occurring  familial  prion 
diseases  [9-11,6].  Previously,  using  two  models 
expressing either the mutations at residue 183 from Thr 
to  Ala  (PrP
T183A)  or  at  residue  198  from  Phe  to  Ser 
(PrP
F198S),  we  discovered  a  PK-resistant  PrP  (PrP
res) 
species  that  exhibited  higher  affinity  for  anti-PrP 
monoclonal  antibody  1E4,  with  an  epitope  between 
residues 97 and 105 [6], compared to anti-PrP antibody 
3F4, an antibody widely-used in the detection of human 
prions with an epitope between residues 106 and 112 
[12].  Furthermore,  we  demonstrated  that  the 
immunoreactivity  behavior  and  gel  mobility  of  this 
PrP
res  is  virtually  identical  to  those  of PrP
*20  that  we 
observed previously in uninfected brain [4,6], validating 
the cell model for the investigation of the spontaneously 
formed iPrP
C.  
 
In this study, using cells expressing PrP
Wt, PrP
T183A and 
PrP
F198S,  we  made  the  following  observations.  First, 
these  PrP  mutations  increased  aggregation  of  the 
protein,  of  which  PrP
T183A  that  has  been  reported  to 
accumulate  intracellularly  [10]  exhibited  the  highest 
amount  of  iPrP.  Second,  immunofluorescence 
microscopy  demonstrated  that  1E4  had  lower  affinity 
for PrP in cultured cells than 3F4, as on immunoblots. 
Third,  glycans  at  the  second  site  (N197)  are  basic, 
whereas  glycans  at  the  first  site  (N181)  are  acidic. 
Fourth,  the  T183A  mutation  not  only  abolished 
glycosylation at N181, but also altered glycosylation at 
N197.  In  addition  to  the  immaturity  of  the  glycan  at 
N197  reported  previously  [10],  the  composition  of 
N197 may be also changed, as evidenced by the faster 
migration of N197 on PK-resistant PrP
T183A compared 
to that of N181 on the PK-resistant PrP
F198S or PrP
Sc 
from  sCJD.  Fifth,  the  F198S  mutation  also  altered 
glycosylation  at  both  the  first  and  second  sites.  The 
glycosylation on the diglycosylated PrP
F198S seemed to 
be  more  mature  than  that  on  the  monoglycosylated 
protein. Using monoclonal antibodies V14 and V61 that 
differentiate the two monoglycosylated PrP (Moudjou et 
al., 2004), we observed that the mutation blocked the 
V14  epitope,  which  was  mimicked  by  reduction  and 
alkylation, a reaction that often breaks disulfide bond 
and  prevents  re-oxidation  of  the  thiol  group  [13]. 
Although  V61  detected  unglycosylated  PrP  and  PrP 
monoglycosylated at N197 (mono197) in the brain PrP, 
it  failed  to  detect  the  glycosylated  and  de-  or  un-
glycosylated PrP from cultured neuronal cells. Finally, 
electron microscopy revealed that while cells expressing 
PrP
F198S  enhanced  autophagy,  PrP
T183A  seemed  to 
completely  inhibit  autophagy  compared  to  wild-type 
cells.  Our  findings  provide  new  insights  into  the 
molecular  mechanisms  underlying  the  formation  of 
iPrP
C and abnormal folding of mutant proteins.  
 
RESULTS  
 
Prediction of the effects of mutations on molecular 
weights,  charges, and  glycosylation  of  human PrP.  
We first predicated the effects of PrP
T183A and PrP
F198S 
on molecular weights and charges of the protein using 
the  ProtParam  tool  at  the  website  of 
http://web.expasy.org/protparam/ from the ExPASy; the 
molecular weight of the wild type prion protein (PrP
Wt) 
backbone from residues 23 to 231 is 22,834.1 Dalton 
(Da).    Compared  to  PrP
Wt,  the  molecular  weights  of 
PrP
T183A and PrP
F198S were decreased (22,834.1 Da vs. 
22,804.1 Da; 22,834.1 Da vs. 22,774.0 Da). Although 
the molecular weight of PrP
F198S decreased more than 
that  of  PrP
T183A  compared  to  wild  type  controls,  the 
small degree of change in the molecular weight might 
not be detectable by Western blotting. In addition, all 
three  PrP  molecules  exhibited  the  same  molecular 
charge with a theoretical isoelectric point (pI) of 9.39.  
 
The  N-linked  glycosylation  prediction  algorithm 
NetNGlyc  1.0  was  then  used  at 
http://www.cbs.dtu.dk/services/NetNGlyc to predict the 
likelihood of glycosylation at the two consensus sites. 
The NetNGlyc server provides a glycosylation potential 
value between 0 and 1 for each N-linked glycosylation 
site.  A  potential  value  greater  than  0.5  indicates  that 
glycosylation  is  probable  at  the  site.  Using  this 
algorithm,  the  glycosylation  potential  values  of  N181 
and N197 in PrP
Wt were determined to be 0.6636 and 
0.7197, respectively. Notably, the potential value was 
greater at the second site than at the first site in all three 
species  tested  (PrP
Wt,  PrP
T183A  and  PrP
F198S). 
Glycosylation  at  only  N197,  but  not  N181,  was 
predicted  in  the  PrP
T183A  mutation  (0.7196,  almost 
identical to that of PrP
Wt), while the first and second 
glycosylation sites were predicted for PrP
F198S (0.6633 
and  0.6988,  respectively).  Interestingly  though,  the 
potential  value  at  the  second  site  was  decreased  for 
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PrP
F198S compared to that in PrP
Wt (0.6988 vs. 0.7197), 
suggesting  that  the  F198S  mutation  mainly  affects 
glycosylation at N197. The expectation would be that 
the  mutation  from  Phe  to  Ser  at  198  would  increase 
glycosylation [14].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PK-resistant PrP conformers detected preferentially 
by the 1E4 anti-PrP antibody in cultured neuronal 
cells.  As  reported  previously  [10,11,6],  PrP
T183A  and 
PrP
F198S have altered gel profiles, largely because of the 
effect of the mutations on glycosylation. Probed with 
the  3F4  antibody  directed  against  PrP106-110  [12], 
PrP
Wt  migrated  as  three  major  bands  of  one  di-
glycosylated  (~36-48  kDa),  two  mono-glycosylated 
(~34-36  kDa  and  ~32-33  kDa,  respectively),  and  one 
un-glycosylated  (27-28  kDa)  forms  (Fig.  1A,  upper 
panel).  In  contrast,  a  single  band  migrating  at  28-36 
kDa, corresponding to the monoglycosylated PrP, was 
detectable in cell lysates from PrP
T183A expressing cells 
(Fig. 1A, upper panel). Bands migrating at 37-45 kDa 
and  33-36  kDa  corresponding  to  the  di-  and  mono-
glycosylated forms, respectively, were detected in cell 
lysates  from  PrP
F198S  expressing  cells;  the 
unglycosylated form was undetectable. From these data, 
we  can  conclude  that  PrP
T183A  mainly  contains 
monoglycosylated  PrP  at  the  second  site  (mono197), 
whereas  PrP
F198S  contains  one  di-  and  two  separate 
mono-glycosylated PrP occupied at the first (mono181) 
or mono197. After treatment with PK at 25 µg/ml, no 
PrP was detected except from PrP
T183A expressing cells, 
in  which  a  weak  band  with  no  change  in  migration 
remained  when  probed  with  3F4.  This  band  was  un-
digested PrP
T183A.  
 
In contrast, using the anti-PrP monoclonal antibody 1E4 
directed  against  PrP97-105  [6],  untreated  PrP  was 
virtually undetectable in all three cell lysates before PK 
treatment while 1E4 detected mutant, but not wild type, 
PK-resistant forms (Fig. 1A). One theory for this unique 
behavior of the 1E4 antibody is that the 1E4 epitope is 
blocked  in  full-length  PrP,  even  when  subjected  to 
denaturing  conditions  prior  to  Western  blotting,  and 
becomes exposed only when truncated by PK with the 
removal of approximately 60-70 amino acids from the 
N-terminus [6]. 
 
In the cell lysates probed with 1E4, the profile of PK-
resistant PrP
F198S was different from that of PrP
T183A. In 
the  T183A  samples,  1E4  revealed  an  intense  band 
migrating  at  23-25  kDa  corresponding  to  the  PK-
resistant  monoglycosylated  species  (Fig.  1A,  lower 
panel). PrP
F198S had two PK-resistant bands: a ~32-39 
kDa band corresponding to di-glycosylated PrP and a 
~26-29  kDa  band  corresponding  to  monoglycosylated 
PrP (Fig. 1A, lower panel). Interestingly, the mobility of 
di-  but  not  mono-glycosylated  PrP
F198S  was  slightly 
slower than that of PK-resistant PrP
Sc from sCJD (Fig. 
1A,  lower  panel)  while  the  mobility  of  the 
monoglycosylated PrP
T183A (second site) was faster not 
only than that of the monoglycosylated form of PrP
F198S 
from cell lysates, but also than that of PrP
res from the 
CJD  brain  control.  Because  the  monoglycosylated 
PrP
T183A carries glycans at the second glycosylation site 
at  residue  197,  the  monoglycosylated  form  of  PrP
res 
from  CJD  brains  and  of  PrP
F198S  from  cultured  cells 
with slower migration may represent glycans at the first 
glycosylation  site,  residue  181.  Another  possibility  is 
that  the  glycans  at  the  N197  site  are  modified 
differently  and  consequently  migrate  slower  than 
glycans from PrP
T183A. 
 
Utilizing immunofluorescence tagging and microscopy, 
we next compared cells expressing PrP
Wt, PrP
T183A and 
PrP
F198S  by  immunostaining  with  1E4  or  3F4. 
Consistent  with  Western  blotting,  all  three  cell  types 
exhibited  greater  immunostaining  with  3F4  than  with 
1E4 (Fig. 1B). Notably, although weak, PrP
Wt and two 
PrP mutants became detectable by immunofluorescence 
with 1E4, in contrast to results by Western blotting with 
Figure 1. Detection of untreated and PK-treated PrP from 
three types of cultured cells with 3F4 and 1E4. A: Western 
blotting of cell lysates with or without PK-treatment at 25 μg/ml) 
probed  with  3F4  (upper  panel)  and  1E4  (lower  panel).  WT: 
Lysates  of  cells  expressing  PrP
Wt.  T183A:  Lysates  of  cells 
expressing PrP
T183A mutation. F198S: Lysates of cells expressing 
PrP
F198S. T2: PrP
Sc type 2 control from sCJD. Di: Diglycosylated 
PrP. Mono181: PrP monoglycosylated at the first site. Mono197: 
PrP  monoglycosylated  at  the  second  site.  Un:  Unglycosylated 
PrP. Comparison of affinities of 1E4 and 3F4 antibodies to the 
full-length and N-terminally truncated human PrP. The dashed-
lines are used to align PrP bands on the blots. 
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1E4  shown  in  Fig.  1A.  In  addition,  as  demonstrated 
previously,  PrP
T183A  is  most  likely  located 
intracellularly, while wild type and PrP
F198S are present 
on  the  cell  surface  [10].  3F4  immunostaining  was 
reduced to almost insignificant levels when wild type 
cells  were  treated  with  PK  (Fig.  1B),  consistent  with 
Western  blotting  results.  In  contrast,  1E4 
immunostaining  was  decreased  after  PK-treatment, 
which was opposite to that observed in Western blots.  
 
Comparison of PrP oligomeric state between wild-
type  and  mutant  PrP.  Sucrose  step  gradient 
sedimentation  is  a  technique  used  to  separate  prion 
protein  species  based  on  their  density,  size,  and 
conformation  [15,4].  In  general,  monomers  or  small 
oligomers  are  often  recovered  in  the  top  fractions, 
whereas large aggregates are recovered in the bottom 
fractions  after  ultracentrifugation  on  the  sucrose  step 
gradients. An increase in the formation of PK-resistant 
PrP  species  in  cells  expressing  mutant  PrP  might  be 
associated  with  an  increase  in  the  aggregation  of  the 
protein.  The  distribution  of  PrP  in  11  sucrose  step 
gradients  fractions  collected  after  ultracentrifugation 
was  determined  by  Western  blotting  probed  with  the 
3F4 antibody. As expected, most PrP
Wt was recovered 
in the top fractions, i.e. fractions 1-2, whereas a small 
Figure 1. Detection of untreated and PK-treated PrP from three types of cultured cells with 3F4 and 1E4. B: 
Immunofluorescence detection of untreated and treated PrP with 3F4 and 1E4. Panels I-III: Cells expressing human PrP
Wt. 
Panels IV-VI: Cells expressing human PrP
T183A. Panels VII-IX: Cells expressing human PrP
F198S. Panels I, IV, and VII: Staining 
with 3F4. Panels II, V, and VIII: Staining with 1E4. Panels III, VI, and IX: Staining without anti-PrP antibodies. Panels X and 
XI: Wild-type cells staining with 1E4 before and after PK-treatment. Panels XII and XIII: Wild-type cells staining with 3F4 
before and after PK-treatment. 
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amount of PrP was observed in fraction 10. In contrast, 
significant amounts of PrP
T183A were recovered in the 
bottom fractions, whereas no PrP
T183A was detected in 
fraction  1.  Only  a  very  small  amount  of  PrP  was 
observed  in  fraction  2  (Fig.  2A,  middle  panel). 
Compared  to  PrP
Wt,  although  most  of  PrP
F198S  was 
distributed in the top fractions 1-2, an increased amount 
of  PrP
F198S  was  also  recovered  in  bottom  fractions, 
especially in fraction 10 (Fig. 2A, lower panel). 
 
To determine which fractions contain PK-resistant wild-
type or mutant PrP, we treated PrP from fractions 1 to 
11  with  PK  and  PNGase  F  (Fig.  2B).  PK-resistant 
PrP
T183A was only detected in fractions 10 and 11 when 
probed with 3F4; other fractions did not show any PK-
resistance. In addition, 3F4 did not detect PK resistant 
wild type and F198S mutant PrP in any sucrose gradient 
fraction,  while  1E4  detected  PK-resistant  iPrP  in  all 
three  PrP  species,  with  the  highest  intensity  in  the 
T183A mutant PrP (Fig. 2B). However, small amounts 
of PK-resistant PrP were only observed in fraction 10 
for PrP
Wt and PrP
F198S, whereas a larger amount of PK-
resistant  PrP  was  detected in  fractions  10  and 11  for 
PrP
T183A. 
 
Two-dimensional gel electrophoresis of iPrP
C from 
cultured neuronal cells expressing PrP
Wt, PrP
T183A, 
or  PrP
F198S.  The  above  one-dimensional  (1-D) 
electrophoresis  and  immunoblotting  clearly  indicated 
that glycans at the two N-linked glycosylation sites of 
the PK-resistant iPrP
C are different in their molecular 
weight: the monoglycosylated PrP species at the second 
site, residue 197 (mono197), migrated faster than those 
monoglycosylated  at  the  first  site,  residue  181 
Figure 2. Detection of oligomeric state of wild-type and mutant PrP. PrP from three types of cells were 
subjected to sucrose step gradient sedimentation. A: PrP in the fractions of the gradients was detected by 
Western blotting with 3F4. Upper panel: PrP
Wt. Middle panel: PrP
T183A. Lower panel: PrP
F198S. B: PrP in fractions 
9-12 was treated with PK and PNGase F prior to Western blotting with 3F4 (upper panel) and 1E4 (lower panel).  
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 (mono181). Taking advantage of the unique PrP
T183A 
mutation that eliminates the first but retains the second 
glycosylation site, we next asked whether mono197 and 
mono181  have  distinct  molecular  charges  by  two-
dimensional (2-D) gel electrophoresis, a technique that 
separates proteins based on both molecular weight and 
molecular charge. The gene 5 protein (g5p) was  first 
used to isolate iPrP
C from the three types of cell lysates, 
following a previously described protocol [4,6].  
 
Similar  to  1-D  immunoblotting,  no  convincing  PK-
resistant PrP
Wt spots were detected by 3F4 or 1E4 on 2-
D  blots  (data  not  shown).  However,  the  two  PK-
resistant mutants were detected by both 1E4 and 3F4, 
although the PrP intensity of the former was 5-10 fold 
greater using 1E4 compared to 3F4. The T183A mutant 
blots  probed  with  3F4  showed  PK-resistant  prion 
protein migrating at 23-26 kDa with isoelectric points 
(pI) from pH 8.0 to 9.5. An intense spot at pH 8.8 was 
also detected (Fig. 3A, arrow). These spots are believed 
to correspond to mono197 since the first glycosylation 
site is eliminated by the T183A mutation. The F198S 
mutant protein migrated at ~36-38 kDa with pI from pH 
4.5 to 5.5. Based on their molecular weights, these spots 
represent  di-glycosylated  PrP  species  (Fig.  3B). 
However, spots detected using the 1E4 antibody were 
more  intense  and  had  noticeable  differences  on  both 
blots. PrP
T183A spots detected by 1E4 migrating at ~22-
27  kDa  corresponding  to  mono197  were  mainly 
detected in a range from pH 7.5 to 10.0 with faint spots 
also detectable at pH 4 (Fig. 3C). PrP
F198S spots were 
mainly detected between pH 4.5 and 6 migrating at ~35-
39  kDa,  corresponding  to  di-glycosylated  forms  (Fig. 
3D). Two populations of faint PrP spots migrating at 
~27-30 kDa were also detected between pH 6.2 and 7.2 
as well as between pH 8.0 and 9.5, corresponding to 
mono181 or mono197. Spots migrating at ~27-30 could 
be PrP species monoglycosylated at the first site since 
they shared the similar molecular weight with mono181 
identified  by  1-D  blotting  (Fig.  1  and  3D),  whereas 
spots between pH 8.0 and 9.5 migrating at ~24-26 kDa 
could be the monoglycosylated at the second site (Fig. 
3D).  
 
After treatment with PK and PNGase F, the two mutants 
exhibited PK-resistant forms, but not the wild type (Fig. 
Figure 3. Two-dimensional gel electrophoresis and blotting of wild-type and mutant PrP captured by 
g5p and treated with PK or with PK plus PNGase F. A-D: Cell lysates containing PrP
T183A (A and C) or PrP
F198S (B 
and D) were treated with PK at 25 μg/ml prior to Western blotting. E-J: Cell lysates containing PrP
Wt (E and H), PrP
T183A 
(F and I), or PrP
F198S (G and J) were treated with PK plus PNGase F prior to Western blotting. PrP spots are highlighted 
by arrows. The dashed-lines are aligned with molecular weight makers. Blots A, B, E, F, and G were probed with 3F4, 
whereas blots C, D, H, I, and J were probed with 1E4. 
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3E-G).  The  PK-resistant  PrP
T183A  and  PrP
F198S  forms 
detected with 3F4 exhibited similar gel mobility at 19-
20  kDa  with  pH  between  7.0  and  9.5  on  the  blots, 
although there was a slight difference in pH between the 
most  intense  spots  (Fig.  3F  and  3G).  However,  in 
samples probed with the 1E4 antibody, the PK-resistant 
iPrP
C became detectable even for PrP
Wt. The faint wild 
type  spots  migrating  at  ~19-20  kDa  with  pH  7.5-8.5 
(Fig. 3H) while more intense PK-resistant PrP
T183A and 
PrP
F198S spots were detected with similar gel mobility 
migrating at ~19-20 kDa and pH 7-9.5 (Fig. 3I and 3J). 
Furthermore,  these  2-D  analyses  of  glycosylated  and 
deglycosylated PK-resistant mutant iPrP indicated that 
glycans  at  the  second  site  are  more  basic,  whereas 
glycans  at  the  first  site  are  more  acidic.  2-D  blots, 
similar to the 1-D immunoblotting, also demonstrated 
that  1E4  has  higher  affinity  for  PK-resistant  iPrP 
compared to 3F4. As indicated above, the effect of the 
two  mutations  by  themselves  on  the  charge  of  the 
proteins was not predicted. Two possibilities that may 
explain the slight differences in the pH of intense spots 
after deglycosylation: the three types of proteins have 
either  distinct  N-terminal  protease  cleavage  sites  or 
distinct GPI anchors.  
 
Detection of PrP
Wt, PrP
T183A, or PrP
F198S with anti-
PrP  antibodies  directed  against  different  N-linked 
glycosylation sites. Previous studies indicated that PK-
resistant  monoglycosylated  PrP
T183A  has  a  molecular 
weight  lower  than  the  PK-resistant  monoglycosylated 
PrP
F198S or PrP
Sc. This observation may be due to two 
possibilities: First, there may be abnormal glycosylation 
at N197 on PrP
T183A, even though this mutation directly 
eliminates  N181.  Second,  the  molecular  weight  the 
Figure 4. Western blotting of PrP with V14 and V61. A: PrP
Sc from sCJD untreated or treated with PK or PK 
plus PNGase F was probed with V14 or V61. B: PrP
Wt, PrP
T183A or PrP
F198S from cells untreated or treated with PNGase 
F was probed with V14 or V61.  
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glycans  is  greater  in  mono181  than  in  mono197. 
However, this hypothesis is inconsistent with a previous 
report  [16].  In  the  previous  study,  two  monoclonal 
antibodies termed V14 and V61 were generated using 
recombinant  sheep  PrP  as  an  immunogen  to  produce 
glycan-controlled epitopes on the PrP molecule, which 
discriminate between the two monoglycosylated species 
[16,17].  Notably,  the  epitopes  recognized  by  the  two 
antibodies  were  identified  in  2.5-Å-resolution  crystal 
structures  of  the  PrP-antibody  complex;  the  epitopes 
could  not  be  mapped  using  conventional  peptide 
scanning  [16,18,  17].  It  was  observed  that  the  V14 
epitope  is  localized  between  sheep  PrP188  and  199 
corresponding to human PrP185-196, whereas the V61 
epitope has not been determined precisely yet. The V61 
epitope  was  deduced  to  locate  in  the  region  before 
amino acid 171 to the first glycosylation site [16,17]. 
Interestingly,  although  both  antibodies  recognize 
unglycosylated PrP, V14 binds to PrP with the first Asn 
glycosylation  site  occupied  (corresponding  to  human 
mono181)  and V61  binds  to PrP  carrying  the  second 
glycosylation site (corresponding to human mono197) 
from sheep, humans, hamsters, and mice.  It was also 
reported that the glycan chain was smaller at the first 
glycosylation site than at the second site [16].  
 
We first examined PrP
Sc that was untreated, treated with 
PK alone, or treated with PK plus PNGase F from sCJD 
brains with the two antibodies. Without PK or PNGase 
F treatment, five major PrP bands were detected by V14 
(Fig. 4A). Based on the molecular weight, the top band 
migrating  at  ~33-35  kDa  represents  the 
monoglycosylated PrP species. Since V14 detects PrP 
species  monoglycosylated  at  N181,  this  band  is 
mono181.  The  second band  migrating  at  ~29-32  kDa 
corresponds to the unglycosylated full-length PrP. The 
third band migrating at ~ 23-25 is the monoglycosylated 
C1 fragment with the first site occupied (mono181- C1). 
The  fourth  band  migrating  at  19-20  kDa  is  the 
unglycosylated  C2  fragment,  an  endogenously  N-
terminally  truncated  PrP  fragment  detected  in  CJD 
brains [19]. Finally, the fifth band migrating at ~18 kDa 
is unglycosylated C1 that is N-terminally truncated in 
normal  brains  [19].  After  PK-treatment,  only  three 
major  bands  are  detectable  with  V14.  The  top  band 
migrating  at  ~26-28  is  PK-resistant  PrP 
monoglycosylated at the first site (mono181 +PK). The 
second  band  migrating  at  ~19  kDa  is  PK-resistant 
unglycosylated PrP (Un + PK). The third faint band was 
detected at ~18.5 kDa. In the samples treated with both 
PK and PNGase F, only two bands were detectable: the 
dominant band migrated at ~19-20 kDa, while the other 
migrated at ~18.5 kDa. Compared to the samples treated 
with PK, but without PNGase F, the band migrating at 
~18.5 kDa significantly increased, suggesting that this 
new  fragment  contains  both  glycosylated  and 
unglycosylated  forms.  Moreover,  since  it  was  not 
detected  in  the  untreated  samples,  this  new  fragment 
could be generated by PK digestion in vitro (Fig. 4A, 
left panel).  
 
Although  equal  amounts  of  samples  were  used,  in 
general, the PrP intensity was much lower in samples 
probed with V61 than in samples probed with V14 (Fig. 
4A,  right  panel).  The  intensity  of  PrP  bands  in  the 
untreated  PrP  detected  with  V61  was  weak  and  four 
bands  could  be  identified.  The  top  double  bands 
migrating at 34-36 kDa corresponds to the PrP species 
monoglycosylated  at  the  second  glycosylation  site 
(mono197  -PK).  The  band  migrating  at  ~29-31  kDa 
corresponds to the unglycosylated full-length PrP. The 
band  migrating  at  ~27-28  kDa  represents  C1 
monoglycosylated  at  the  second  site  (mono197-C1). 
After treatment with PK, two bands became detectable 
migrating at ~29-30 kDa and 19-20 kDa, respectively. 
Since  V61  detected  the  monoglycosylated  species 
occupied at residue 197, they represent the PK-resistant 
PrP  species  monoglycosylated  at  the  second  site 
(mono197  +PK)  and  PK-resistant  deglycosylated  and 
unglycosylated forms (Un +PK).  Consistent with the 
observation by Moudjou et al., the migration of the PrP 
mono197 detected with V61 was slower than that of PrP 
mono181 detected with V14 (Fig. 4A). Therefore, using 
the  two  antibodies,  we  observed  that  the  human  PK-
resistant  PrP  species  monoglycosylated  at  the  second 
site (mono197) has a higher molecular weight than that 
monoglycosylated  at  the  first  site  (mono181).  In 
addition,  both  antibodies  were  unable  to  detect  di-
glycosylated  human PrP, consistent  with  the  previous 
observation by Moudjou et al. [16]. 
 
In cultured neuronal cell lysates containing PrP
Wt, four 
major bands were detected by V14, migrating at ~33-35 
kDa, ~29-32 kDa, ~23-25 kDa, and ~18 kDa (Fig. 4B, 
left  panel).  They  correspond  to  mono181, 
unglycosylated  PrP,  mono181-C1,  and  unglycosylated 
C1. Compared to PrP
Sc from sCJD in Fig. 4A, C2 was 
dramatically decreased in uninfected cell lysates. After 
treatment  with  PNGase  F,  only  two  bands  were 
detected, corresponding to deglycosylated full-length at 
~29-32 kDa and N-terminally truncated C1 at 18 kDa. 
V14  mainly  detected  the  unglycosylated  PrP
T183A 
migrating  at  ~29-32  kDa.  Faint  bands  were  also 
detected  migrating  at  ~19  kDa  and  18  kDa 
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corresponding to C2 and C1, respectively (Fig. 4B, left 
panel).  After  deglycosylation  with  PNGase  F,  two 
bands  corresponding  to  deglycosylated  and 
unglycosylated  full-length  and  N-terminally  truncated 
PrP  molecules  were  detected  by  V14.  In  contrast,  no 
bands  were detected  by  V14  in  treated  and  untreated 
cell  lysates  containing  PrP
F198S.  Surprisingly,  no  PrP 
bands  were  detected  by  V61  in  all  three  cell  lysates 
untreated  and  treated  with  PNGase  F  (Fig.  4B,  right 
panel).  Using  the  two  antibodies  we  were  unable  to 
address issues why the migration of the mono197 from 
PrP
T183A  is  faster  than  that  of  PrP
F198S  because  of 
inability  of  V14  to  detect  PrP
F198S  and  because  of 
inability of V61 to detect both wild-type and mutant PrP 
from  cultured  cell  lysates.  Nevertheless,  our  current 
study  revealed  that  V14  identified  a  C1 
monoglycosylated  at  the  second  glycosylation  site 
(mono197-C1). Moreover, our new results for the first 
time indicated that F198S mutation blocked the binding 
of  V14  to  PrP  and  the  V61  epitope  was  completely 
blocked in both wild-type and mutant PrP from cultured 
cells.  
 
Effect  of  reduction  and  alkylation  on  the 
accessibility of the V14 epitope and epitope mapping 
with a peptide array. The inability of V14 to detect 
PrP
F198S raises two possibilities: First, the residue Phe 
itself  is  a  key  element  of  the  epitope  and  the  F198S 
mutation completely blocks V14 binding. However, the 
residue Phe is out of the V14 epitope, as demonstrated 
by the X-ray crystallography study [18,17], which does 
not  support  this  possibility.  Second,  although  residue 
Phe  itself  is  not  part  of  the  epitope,  F198S  mutation 
may affect the disulfide bond between residues 179 and 
214, which blocks the accessibility of the V14 epitope. 
To rule out this possibility, we next used V14 to detect 
PrP  treated  with  a  reducing  reagent  tributylphosphine 
(TBP)  and  an  alkylating  reagent  mechlorethamine 
(MCT) that break disulfide bond and block the free thiol 
group.  
 
In addition to the V14 antibody, three other antibodies 
were used as controls: 3F4 directed against PrP105-112, 
6H4  directed  against  PrP145-152  and  anti-C  against 
PrP220-231.  All  antibodies  detected  untreated 
recombinant  human  PrP23-231,  while  they  also 
detected PrP in samples treated with TBP or MCT alone 
(Fig.  5).  Treatment  with  TBP  alone  decreased  the 
intensity  of  PrP  probed  with  the  four  antibodies. 
However, V14 detected no PrP at all in samples treated 
with  TBP  and  MCT  together,  while  3F4  and  anti-C 
antibodies  still  detected  PrP  (Fig.  5).  This  result  is 
similar to our previous observation with 6H4 [13,20].  
We  previously  used  peptide  membrane  array,  a 
technique  that  has  often  been  used  to  map  antibody 
epitopes, to re-map epitopes of 1E4 and 3F4 antibodies 
[6,12].  However,  here  we  were  unable  to  find 
convincing epitopes for V14 and V61 antibodies using a 
99  13-mer  peptide  membrane  array  that  covers  the 
entire  human  PrP  sequence  from  residues  23  to  231 
(data  not  shown).  Our  result  is  consistent  with  the 
observation reported by Moudjou et al. [16], suggesting 
that  they  have  conformational  epitopes  even  though 
they are able to detect the denatured PrP on Western 
blots.  
 
Comparison of glycan modification between PrP
T183A 
and PrP
F198S by treatment with Endo H and PNGase 
F. We treated PrP
Wt, PrP
T183A and PrP
F198S with Endo H, 
or PNGase F that cleaves N-linked glycans. The Endo H 
treatment  did  not  significantly  change  the  gel  profile 
and glycoform ratios of PrP
Wt (Fig. 6A). In contrast, it 
did  significantly  reduce  the  intensity  of  the 
monoglycosylated PrP
T183A and increase the intensity of 
its unglycosylated form (Fig. 6A). No relevant changes 
in  the  intensity  of  di-glycosylated  PrP
F198S  were 
observed,  while  the  two  monoglycosylated  PrP
F198S 
species became undetectable after treatment with Endo 
H, suggesting that Endo H only removes glycans from 
monoglycosylated  PrP  at  the  two  sites.  On  the  other 
hand,  a  faint  band  migrating  at  ~28-29  kDa 
corresponding to the unglycosylated and deglycosylated 
PrP
F198S  was  visible  in  the  treated  sample,  probably 
deriving  from  monoglycosylated  PrP  (Fig.  6A). After 
treatment with PNGase F, all three different PrP species 
were observed to have a band migrating at ~28-29 kDa 
corresponding  to  deglycosylated  and  unglycosylated 
PrP  (Fig.  6A).  However,  only  PrP
Wt  and  PrP
F198S 
exhibited a band migrating at ~20 kDa corresponding to 
endogenously N-terminally truncated fragment C2.  
 
To confirm that Endo H only reduces monoglycosylated 
but  not  di-glycosylated  PrP  species,  we  proceeded  to 
examine Endo H or PNGase F treated PrP
F198S with two 
more antibodies including anti-C and anti-N (Fig. 6B). 
Reaffirming evidence from the 3F4 antibody, both anti-
C and anti-N antibodies also revealed no decreases in 
the  intensity  of  the  di-glycosylated  PrP  but  dramatic 
decreases in the intensity of the monoglycosylated PrP 
species.  PNGase  F  also  removed  all  glycans  from 
PrP
F198S. Using these two antibodies, we also examined 
PrP
Sc  from  sCJD  and  observed  no  changes  in  the 
intensity of both di- and mono-glycosylated PrP species 
after  treatment  with  Endo  H  (Fig.  6C).  Once  again, 
PNGase F removed glycans from PrP
Sc as well. 
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Electron microscopy of three types of cultured cells. 
Since  the  two  mutations  significantly  increased  PrP 
aggregation, as evidenced above by protein chemistry 
studies,  we  asked  whether  there  are  any  changes  in 
organelles and cellular structures induced by mutant PrP 
that readily formed aggregates. Cells expressing PrP
Wt, 
PrP
T183A,  or  PrP
F198S  were  examined  by  electron 
microscopy  (Fig.  7).  Although  most  organelles 
including  mitochondria  and  nucleus  seemed  to  be 
identical  between  these  cells,  the  lysosome  had 
characteristic differences between cells expressing the 
various PrP species. Compared to PrP
Wt cells (Fig. 7A), 
PrP
F198S cells exhibited enhanced autophagy (Fig. 7C), 
while virtually no autophagy was observed in PrP
T183A 
cells (Fig. 7B). 
 
DISCUSSION  
 
The two N-linked glycosylation sites located at residue 
181,  Asn-Ile-Thr  residues  181-183,  and  residue  197, 
Asn-Phe-Thr residues 197-199 [21] have been believed 
to play a crucial role in the stabilization of prion protein 
conformation.  The  naturally  occurring  mutations  at 
residue 183, Thr to Ala (PrP
T183A), or at residue 198, 
Phe to Ser (PrP
F198S), falling in the two consensus sites 
are linked to two distinct familial prion diseases [22,23]. 
Elimination of each of the two sites or two sites together 
by mutagenesis of hamster PrP in CV1 cells induced the 
intracellular  accumulation  of  mutant  proteins  [24]. 
Lehman and Harris observed that mouse PrP mutated at 
T182  alone  or  at  both  T182  and  T198  in  CHO  cells 
failed  to  reach  the  cell  surface  but  those  mutated  at 
T198  did.  Moreover,  all  three  mutant  PrP  acquired 
PrP
Sc-like  physicochemical  properties  reminiscent  of 
PrP
Sc while to a limited extent PrP
Wt did so only when 
synthesized  in  the  presence  of  inhibitor  tunicamycin 
[25].  Using  M17  cells  expressing  human  PrP
N181G  or 
PrP
T183A, Capellari et al. observed that PrP
N181G, but not 
PrP
T183A,  reached  the  cell  surface  even  though  both 
mutations eliminated glycosylation at the first site [10].  
This indicates that the Thr to Ala mutation itself, not the 
elimination  of  the  first  glycosylation  site,  altered  the 
physical properties of the mutant protein [10]. Although 
the  F198S  mutation  falls  within  the  second 
glycosylation  site,  Asn-Phe-Thr  residues  197-199, 
PrP
F198S  slightly  increased  the  efficiency  of 
glycosylation at the first glycosylation site (N181), and 
greatly increased the efficiency of glycosylation at the 
second site (N197) in cultured cells [11].  
 
Our  current  study  indicated  that  the  two  mutant  PrP 
molecules exhibited increased aggregation, although a 
small amount of PrP
Wt aggregates is also evident in the 
absence  of  tunicamycin.  Most  of  PrP
T183A  was  in 
oligomers and large aggregates; virtually no monomeric 
form  was  present.  In  PrP
F198S,  however,  monomeric 
species were still dominant despite an increase in the 
amount of aggregates, since the majority of PrP
F198S was 
recovered in the top fractions of sucrose step gradients. 
The enhanced tendency of PrP
T183A to form aggregates 
may  result  from  the  intracellular  accumulation  of  the 
mutant protein. The F198S mutation did not change the 
ability  of  PrP
F198S  to  reach  the  cell  surface  [11], 
although  the  mutation  may  significantly  change  the 
structure around the V14 epitope previously found to be
Figure 5. Western blotting of the recombinant human 
PrP untreated or treated with MCT or/and TBP probed 
with various anti-PrP antibodies. The recombinant human 
PrP23-231 was treated with MCT alone, TBP alone, or MCT plus 
TBP prior to Western blotting with 3F4, 6H4, V14 and V61. 
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 localized  between  human  PrP185-196  [16,17]. 
Therefore, the majority of the iPrP
C associated with the 
T183A  mutation  may  be  the  result  of  its  PrP 
intracellular  accumulation,  raising  the  possibility  that 
iPrP
C  is  derived  predominantly  from  intracellular  PrP 
species. Immunofluorescence microscopy of tagged PrP 
also indicated that PrP
T183A accumulates within the cell, 
whereas PrP
F198S was distributed both inside the cell and 
on  the  cell  surface,  consistent  with  previous 
observations [10,11]. 
 
In  addition  to  abnormal  protein  folding,  the  two 
mutations  also  significantly  altered  N-linked 
glycosylation.  As  anticipated  by  the  N-linked 
glycosylation  prediction  algorithm  NetNGlyc  1.0  and 
confirmed  by  Western  blot  analysis,  PrP
T183A 
Figure 6. Digestion of wild-type and mutant PrP by Endo H. A: PrP
Wt, PrP
T183A, or PrP
F198S was treated 
with Endo H or PNGase F prior to Western blotting with 3F4. B: PrP
F198S was treated with Endo H or PNGase F 
prior to Western blotting with Anti-C or anti-N. C: PrP
Sc from sCJD was treated with Endo H or PNGase F prior 
to Western blotting with anti-C or anti-N.  
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completely abolishes glycosylation at N181. However, 
PrP
T183A also exhibited altered glycosylation at N197. 
On  1-D  blots,  the  migration  of  the  PK-resistant 
mono197 from PrP
T183A was faster than that of PrP
F198S 
and  of  the  dominant  monoglycosylated  PrP
Sc  from 
sCJD, suggesting that the apparent molecular weight of 
glycans at mono197 is smaller than that of glycans at 
mono181. However, using two monoclonal antibodies 
V14  and  V61,  we  demonstrated  that  the  apparent 
molecular  weight  of  PK-resistant  mono197  of  PrP
Sc 
from  sCJD is greater than that of  mono181 of PrP
Sc, 
consistent  with  the  previous  finding  in  scrapie  PrP
Sc 
[16].  Thus,  the  combination  of  these  results  provides 
further evidence to suggest the altered composition of 
glycans  at  N197  of  PrP
T183A.  Furthermore,  our  2-D 
analyses revealed that pIs of PK-resistant PrP
T183A are 
basic, while the PK-resistant diglycosylated PrP
F198S are 
acidic. Using Endo H, we confirmed that a large amount 
of  glycans  from  PrP
T183A  is  immature,  as  originally 
reported  by  Capellari  et  al.  [10],  and  our  findings 
support  the  hypothesis  that  while  only  some  PrP
T183A 
contains modified glycans (the ~50% Endo H resistant 
molecules),  all  of  the  PrP
T183A  fails  to  reach  the  cell 
surface.  The  present  study  demonstrated  that  the 
glycans at either the first or second site were virtually 
completely digested by Endo H from monoglycosylated 
PrP
F198S.  Interestingly,  the  glycans  of  di-glycosylated 
PrP
F198S were not significantly digested, suggesting that 
di-glycosylated  PrP
F198S  are  more  mature  than 
monoglycosylated forms. 
 
Glycans in mouse and hamster brain PrP
Sc have been 
characterized by mass spectrometry in previous reports 
[26,27].  Glycosylation  at  each  of  the  two  N-linked 
consensus  sites  of  mouse  ME7  strain  was  directly 
compared by mass spectrometry and differences in N-
glycan populations between the two sites were observed 
[26].  Notably,  although  both  sites  contained  major 
neutral  components,  many  other  minor  neutral 
components were only observed at the first but not the 
second  site.  The  majority  of  glycans  at  the  first  site 
were bi- and tri-antennary structures with a mass range 
of  approximately  1.66-2.34  kDa,  whereas  the  second 
site mainly contained tri- and tetra-antennary structures 
with a mass range of ~2.0-3.02 kDa [26]. Therefore, the 
molecular  mass  of  glycans  was  greater  in  the  second 
site than in the first site, having a difference ranging 
from 0.34-0.68 kDa. The range of oligosaccharides in 
PrP
C  and  PK-resistant  PrP27-30  was  found  to  be 
identical while the relative proportions of some glycans 
were  different  in  the  two  species  [27].  Compared  to 
PrP
C, PrP27-30 had a reduced bisected and an increased 
tri-  and  tetra-antennary  glycans  [27].  Nevertheless,  to 
date no mass spectrometry analysis of the glycans on 
the  human  PrP
Sc  or  the  PK-resistant  human  PrP  has 
been  reported,  and  the  glycans  on  the  two 
monoglycosylated species are not readily differentiated 
by  Western  blotting  using  regular  anti-PrP  antibodies 
such as 3F4.  
 
 
 
 
 
Figure  7.  Transmission  electron  microscopy  of  cells 
expressing  PrP
Wt,  PrP
T183A,  or  PrP
F198S.  A:  Cells  expressing 
PrP
Wt.  B: Cells expressing PrP
T183A. C: Cells expressing PrP
F198S. 
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V14  and  V61  are  well-characterized  antibodies  that 
were generated with the recombinant sheep PrP as the 
immunogen  but  are  able  to  discriminate  the  two  PrP 
species monoglycosylated either at the first or second 
glycosylation site of sheep, human, hamster and mouse 
[16]. In addition to recognizing the unglycosylated PrP, 
V14 also recognizes the PrP species monoglycosylated 
at the first site, while V61 recognizes the PrP species 
monoglycosylated at the second site. Using these two 
antibodies, it was confirmed that the molecular mass of 
glycans is greater at the second than the first site [16]. 
Although V14 also detected the di-glycosylated sheep 
PrP
C  but  it  did  not  detect  the  di-glycosylated  sheep 
PrP
Sc.  Our  data  indicated  that  the  molecular  mass  of 
glycans is greater at the second than the first site on the 
human  PK-resistant  PrP
Sc  from  sCJD,  similar  to  that 
observed in scrapie PrP
Sc [16]. However, the molecular 
mass of glycans at the second site of PrP
T183A seemed to 
be smaller than that of glycans on the second site of 
PrP
F198S or brain PrP
Sc of sCJD. This provides further 
evidence  that  the  T183A  mutation  perturbs  the 
glycosylation  at  the  second  site.  Furthermore,  our 
present  study  demonstrated  that  the  PrP
F198S  species 
monoglycosylated  at  the  first  and  second  sites  were 
undetectable after the Endo H treatment. Therefore, the 
F198S mutation similarly alters glycosylation not only 
at  the  second,  but  also  the  first  site.  However,  the 
glycans  on  the  di-glycosylated  PrP
F198S  were  not 
cleaved by Endo H, indicating that glycans on the di-
glycosylated PrP are mature.  Although the epitopes of 
V14,  localized  at  sheep PrP188-199  corresponding  to 
human  PrP185-196,  and  V61,  localized  at  sheep 
PrP169-174 corresponding to human PrP166-171, were 
mapped  by  studying  the  2.5-Å  resolution  PrP-Fab 
crystal  complex,  the  conventional  peptide  scanning 
failed to localize them on the PrP sequence [16,18,17]. 
As  a  result,  the  epitopes  have  been  believed  to  be 
conformation-dependent  [16],  which  is  in  agreement 
with our results reported here. We have demonstrated 
previously  that  reduction  and  alkylation  blocks  the 
accessibility of the 6H4 epitope but not epitopes of 3F4 
and anti-C by breaking the disulfide bond of PrP [13]. 
In the current study, data revealed that the reduction of 
PrP  by  TBP  decreased  the  accessibility  of  the  V14 
epitope and a combination of reduction and alkylation 
completely  blocked  its  accessibility,  providing  further 
evidence  that  the  accessibility  of  the  V14  epitope 
depends on an intact disulfide bond on the C-terminal 
PrP.  The  V14  epitope  was  blocked  by  the  F198S 
mutation as well, suggesting that the F198S mutation 
may  also  rupture  the  disulfide  bond.  These  results 
parallel discoveries with other conformational sensitive 
anti-PrP  antibodies,  including  8H4,  which  was  also 
reported to have the lower affinity for PrP
F198S than for 
PrP
Wt [11]. Unexpectedly, V61 detected no glycosylated 
and unglycosylated PrP species from all three types of 
cultured cells even though it detected brain PrP
C and 
PrP
Sc. Why the V61 epitope becomes inaccessible in all 
wild-type  and  mutant  PrP  species  remains  to  be 
determined. Since the amount of PrP
Wt used seemed to 
be large, indicated by V14 (Fig. 4B), it is most unlikely 
that inability of V61 to detect PrP from cultured cells 
mainly resulted from its lower affinity for PrP. 
 
Autophagy  degrades  organelles  and  unfolded  proteins 
through the lysosomal pathway and has been considered 
a  key  adaptive  response  that  can  prevent  death  in 
stressed  or  diseased  cells  [28].  This  natural  process 
normally occurs at a basal level in cells and it can be 
induced by a variety of conditions [29]. Using electron 
microscopy,  we  observed  that  autophagy  was  slightly 
increased in cells expressing PrP
F198S compared to cells 
expressing  PrP
Wt.  Surprisingly,  autophagy  was 
dramatically  decreased  in  cells  expressing  human 
PrP
T183A,  which  further  highlights  a  possible 
paradoxical  relationship  between  autophagy  and 
aggregation, since the largest amounts of PrP aggregates 
were  also  observed  in  cells  expressing  the  T183A 
mutant. It is worth noting that cytosolic PrP aggregates 
were recently observed to activate reticulon 3 (RTN3), 
which inhibited autophagy and impeded the clearance 
of cytosolic PrP aggregates in vitro [30]. Furthermore, it 
was revealed that RTN3 activation was mediated by the 
enhanced interaction between Bcl-2 and beclin 1 [30]. 
Since autophagy is believed to play either a pro-survival 
or  a  pro-death  role,  determining  the  molecular 
mechanisms underlying the differences in the induction 
of autophagy using our cell models would present an 
important avenue for developing therapeutic strategies 
for protein folding disorders. 
 
The physiology and pathophysiology of iPrP
C currently 
remain unclear. While it has been proposed that iPrP
C is 
involved  in  prion  and  Alzheimer  diseases  and  in  the 
long-term  memory  storage  according  to  our  recent 
findings  [31-34],  new  insights  into  the  mechanisms 
underlying the spontaneous formation of PrP aggregates 
obtained  with  cell  models  would  be  significant  in 
enhancing our understanding of not only prion diseases 
but also other diseases involving protein misfolding. 
 
MATERIALS AND METHODS 
 
Reagents and antibodies    
 
Phenylmethylsulfonyl  fluoride  (PMSF),  PK,  N,  N’-
diisopropylcarbodiimide,  1-hydroxybenzotriazole, 
trifluoroacetic  acid,  piperidine,  triisobutylsilane,  and 
dichloromethane were purchased from Sigma Chemical 
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Co. (St. Louis, MO). Peptide N-glycosidase F (PNGase 
F) was purchased from New England Biolabs (Beverly, 
MA) and used according to the manufacturer’s protocol. 
Reagents  included  Amino-PEG  cellulose  membranes 
and Fmoc-amino acids were obtained from Intavis (San 
Marcos,  CA).  N-α-Fmoc-O-benzyl-L-phosphoserine 
and  N-α-Fmoc-O-benzyl-L-phosphothreonine  were 
purchased from AnaSpec (San Jose, CA). Reagents for 
enhanced chemiluminescence (ECL Plus) were obtained 
from Amersham Pharmacia Biotech, Inc. (Piscataway, 
NJ).  Magnetic  beads  (Dynabeads  M-280, 
tosylactivated)  were  from  Dynal  Co.  (Oslo, Norway). 
The  recombinant  human  PrP23-231  was  kindly 
provided  by  Dr.  Witold  K.  Surewicz  from  the 
Department  of  Physiology  and  Biophysics,  Case 
Western  Reserve  University.  The  gene  5  protein  was 
kindly  provided  by  Drs  Geoff  Kneale  and  John 
McGeehan  from  Biophysics  Laboratories,  Institute  of 
Biomedical  and  Biomolecular  Sciences,  University  of 
Portsmouth,  Portsmouth,  United  Kingdom.  Anti-PrP 
antibodies, including mouse monoclonal antibody 3F4 
against human PrP residues 106-110 [12], 6H4 against 
human PrP145-152, 1E4 against human PrP 97-105 [6] 
(Cell Sciences, Inc., Canton, MA), V14 against human 
PrP185-196  [16],  V61  against  approximately  before 
human  PrP168  to  residue  181  [16],  anti-C  against 
PrP220-231 and anti-N against PrP30-40 [19] were also 
used. 
 
Cloning and production of cell lines 
 
M-17 human neuroblastoma cells were transfected with 
the episomal vector CEP4β containing a prion coding 
sequence  using  the  cationic  lipid  DOTAP  (Roche 
Applied  Science)  as  previously  described  [9,10,11]. 
Transfected  cells  were  grown  as  bulk  selected 
hygromycin-resistant  cultures  at  37ºC  in  OPTI-MEM 
with 5% calf serum supplement, iron-enriched (GIBCO-
BRL) and 500 µg/ml Hygromycin B (Calbiochem, La 
Jolla,  CA).  For  each  experiment,  cells  were  removed 
from  the  flask  with  trypsin,  and  counted;  the  same 
number of cells from each cell culture was seeded onto 
Petri  plates.  They  were  incubated  overnight  to  ~95% 
confluence  in  complete  medium  supplemented  with 
serum and antibiotics. 
 
Brain tissues and preparation of brain homogenates 
 
Consent to use autopsy material for research purposes 
was obtained for all samples. Autopsy was performed 
within  20  h  after  death.  Biopsy  brain  tissues  were 
immediately frozen in liquid nitrogen, then transferred 
to  -80ºC  for  future  use.  The  10%  (w/v)  brain 
homogenates were prepared in 9 volumes of lysis buffer 
(10 mM Tris, 100 mM NaCl, 0.5% Nonidet P-40, 0.5% 
deoxycholate,  10  mM  EDTA,  pH  7.4).  As  required, 
brain homogenates were centrifuged at 1000 g for 10 
min  at  4C  to  collect  the  supernatant  (S1).  For  PK-
digestion,  samples  were  incubated  with  designated 
amounts of PK at 37ºC for 1 h and the reaction was 
terminated  through  the  addition  of  PMSF  at  a  final 
concentration  of  3  mM  and  boiling  in  SDS  sample 
buffer (3% SDS, 2 mM EDTA, 4% β-mercaptoethanol, 
10% glycerol, 50 mM Tris, pH 6.8) for 10 minutes. 
 
Cell lysis 
 
After  removal  of  the  media,  cells  were  rinsed  three 
times with PBS and lysed in 1.2 ml of lysis buffer on 
ice for 30 min. The cell lysates were centrifuged at 1000 
g for 10 min at 4ºC to remove nuclei and cellular debris. 
The  supernatant  was  incubated  with  5.5  ml  of  pre-
chilled methanol at -80ºC for 2 h and centrifuged at 14 
000 g for 30 min at 4ºC. The pellet was resuspended in 
100 µl of lysis buffer. 
 
Epitope mapping by peptide membrane arrays 
 
The general methods for preparing multiple overlapping 
peptides  bound  to  cellulose  membranes  have  been 
described  in  detail  [35,6,12].  After blocking  with  5% 
skim milk in TBS-T at 37ºC for 2 h, the prion peptide 
membrane  was  probed  with  3F4  at  1:10,000,  1E4  at 
1:500, V14 at 1:100, or V61 at 1:10 in 1% skim milk for 
2 h at 37ºC. The membrane was washed with TBS-T, 
then  incubated  at  37ºC  with  1:4,000  HRP-conjugated 
sheep anti-mouse IgG for 1 h. After a final wash and 
developing  with  ECL  Western  blotting  detection 
reagent  (Amersham  Pharmacia),  the  membrane  was 
visualized  by  using  Bio-Rad  Fluorescent  Imager.  The 
control  membrane  was  probed  only  with  HRP-
conjugated  sheep  anti-mouse  IgG  without  primary 
antibody. 
 
Specific capture of abnormal PrP by g5p   
 
The g5p molecule (100 µg) was conjugated to 7 x 10
8 
tosyl activated magnetic beads in 1 ml of PBS at 37C 
for  20  h  [36,4].  The  g5p-conjugated  beads  were 
incubated with 0.1 % BSA in PBS to block non-specific 
binding. The prepared g5p beads were stable for at least 
3 months at 4
oC. The specific capture of PrP
Sc by g5p 
was  performed  as  described  [36,4]  by  incubating  S1 
fractions and g5p conjugated beads (10 µg g5p/6 x 10
7 
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beads) in 1 ml of binding  buffer (3% Tween-20, 3% 
NP-40 in PBS, pH 7.5). After incubation with constant 
rotation  overnight  at  room  temperature,  the  PrP-
containing g5p beads were collected with an external 
magnetic  force  and  all  unbound  molecules  in  the 
solution were removed.  Following three rinses in the 
wash  buffer  (2%  Tween-20  and  2%  Nonidet  P-40  in 
PBS, pH 7.5), the g5p beads were resuspended in SDS 
sample buffer (3% SDS, 2 mM EDTA, 10% glycerol, 
50 mM Tris, pH 6.8) and heated at 95
oC for 5 min to 
release bound proteins.  
 
Reduction and Alkylation of PrP   
 
Recombinant PrP was boiled in equal volume of 2 X 
sample buffer (6% sodium dodecyl sulfate (SDS), 5% 
β-mercaptoethanol  (β-ME),  4  mM  EDTA,  20% 
glycerol,  125  mM  Tris-HCl,  pH  6.8)  as  described 
previously [13]. The samples were incubated with a 5-
fold volume of pre-chilled methanol at -20 ºC for 2 h, 
followed by a centrifugation at 16,000 g for 20 min at 4 
ºC. Pellets were resuspended in 20 µl of TBP buffer (5 
mM TBP, 8 M urea, 2% CHAPS, 20 mM Tris-HCl, pH 
8.0) for 1 h at room temperature and then incubated in 
the dark with alkylating antitumor drugs for designated 
time.  The  samples  were  incubated  with  pre-chilled 
methanol and centrifuged at 16,000 g for 20 min at 4 ºC. 
Finally, the pellets were resuspended in 20 µl samples 
buffer and subjected to SDS-PAGE and immunoblotting 
with various anti-PrP antibodies. 
 
Velocity sedimentation in sucrose step gradients 
 
Cell lysates were incubated with an equal volume of 2% 
Sarcosyl for 30 min on ice. The sample was loaded atop 
10-60%  step  sucrose  gradients  and  centrifuged  at 
200,000  x  g  in  the  SW55  rotor  for  1  h  at  4ºC  as 
described  with  minor  modification  [4].  After 
centrifugation, the contents of the centrifuge tubes were 
sequentially  removed  from  the  top  to  the  bottom  to 
collect  11  fractions.  Aliquots  of  11  fractions  were 
subjected to immunoblot analysis described below. 
 
Electronic microscopy of cultured neuronal cells 
 
Cells  cultured  on  the  ACLAR
©  embedding  film 
(Electron  Microscopy  Sciences,  Hatfield,  PA)  were 
fixed  with  2.5%  glutaraldehyde  in  0.1  M  Millonigs' 
phosphate  buffer  (pH  f.4)  for  two  hours  at  room 
temperature. After a rinse in 0.1 M phosphate buffer, 
the  cells  were  postfixed  in  ferrocyanide-reduced 
osmium  tetroxide  (Karnovsky,  1971)  for  two  hours, 
then  rinsed  in  distilled  water.  The  cells  were  soaked 
overnight  in  acidified  0.25%  uranyl  acetate.  Another 
rinse  was  followed  by  dehydration  in  ascending 
concentrations  of  ethanol,  passage  through  propylene 
oxide, and embedment in Poly/Bed 812 (Polysciences, 
Warrington, PA). The cells on the ACLAR
© film were 
cross-sectioned. Thin  sections  were  stained  with 
acidified  methanolic  uranyl  acetate,  followed  by 
staining  with  Sato’s  triple  lead  stain  as  modified  by 
Hanaichi et al. [37] and examined in a JEOL 1200EX 
electron microscope. 
 
Immunofluorescence microscopy 
 
For  immunofluorescence  staining  of  PrP  without  PK 
comparison,  transfected  cells  expressing  PrP
Wt, 
PrP
T183A, or PrP
F198S were grown overnight on Poly-D-
lysine  coated  coverslips.  The  cells  were  fixed  in  4% 
paraformaldehyde for 15 minutes at room temperature. 
Blocking was performed with PBST (10% Goat Serum, 
2%  T-20,  1%  Triton  X-100),  for  1  hr  at  room 
temperature  before  rinsing  with  PBS.  The  cells  were 
then incubated with 3F4 (1:4,000) or 1E4 (1:50) at room 
temperature,  rinsed  with  PBS,  followed  with  FITC-
conjugated  goat  anti-mouse  IgG  at  1:320  (Sigma,  St. 
Louis,  MO)  for  1  hour  at  room  temperature  under 
darkness. After washing with PBS, the coverslips were 
mounted on slides using fluorescent mounting medium 
fluoromount with DAPI (Dako, Carpenteria, CA). For 
imunofluorescence staining with PK comparison, wild 
type  cells  were  grown  under  identical  conditions  to 
those  described  above.  They  were  also  fixed  in  4% 
paraformaldehyde for 15 minutes at room temperature. 
The blocking step included PK (10 μg/mL) for the PK 
positive dishes along with PBST. All later conditions 
were  constant,  with  the  exception  of  solely  using 
monoclonal antibody 3F4 (1:4,000).  
 
Western blot analysis 
 
Samples were resolved on 15% Tris-HCl Criterion pre-
cast  gels  (Bio-Rad)  for  SDS  polyacrylamide  gel 
electrophoresis at 150 V for ~80 min.  The proteins on 
the  gels  were  transferred  to  Immobilon-P  membrane 
(PVDF, Millipore) for 2 h at 70V. The membranes were 
incubated for 2 h at room temperature with either 3F4 
(1:40,000), 1E4 (1:1,000), 6H4 (1:6,000), V14 (1:500), 
V61 (1:500), anti-N (1:6,000) or anti-C (1:10,000) as 
the  primary  antibody  for  probing  the  PrP  molecule. 
Following incubation with HRP-conjugated sheep anti-
mouse  IgG  at  1:5,000  for  monoclonal  antibodies  or 
donkey-anti  rabbit  IgG  at  1:6,000,  the  PrP  bands  or 
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spots were visualized on Kodak film by the ECL Plus in 
accordance with the manufacturer’s protocol. 
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